289 related articles for article (PubMed ID: 11792330)
1. Long-term mortality benefit with the combination of stents and abciximab for cardiogenic shock complicating acute myocardial infarction.
Chan AW; Chew DP; Bhatt DL; Moliterno DJ; Topol EJ; Ellis SG
Am J Cardiol; 2002 Jan; 89(2):132-6. PubMed ID: 11792330
[TBL] [Abstract][Full Text] [Related]
2. Results of primary percutaneous transluminal coronary angioplasty plus abciximab with or without stenting for acute myocardial infarction complicated by cardiogenic shock.
Giri S; Mitchel J; Azar RR; Kiernan FJ; Fram DB; McKay RG; Mennett R; Clive J; Hirst JA
Am J Cardiol; 2002 Jan; 89(2):126-31. PubMed ID: 11792329
[TBL] [Abstract][Full Text] [Related]
3. Impact of stents and abciximab on survival from cardiogenic shock treated with percutaneous coronary intervention.
Huang R; Sacks J; Thai H; Goldman S; Morrison DA; Barbiere C; Ohm J
Catheter Cardiovasc Interv; 2005 May; 65(1):25-33. PubMed ID: 15800889
[TBL] [Abstract][Full Text] [Related]
4. Abciximab therapy improves survival in patients with acute myocardial infarction complicated by early cardiogenic shock undergoing coronary artery stent implantation.
Antoniucci D; Valenti R; Migliorini A; Moschi G; Trapani M; Dovellini EV; Bolognese L; Santoro GM
Am J Cardiol; 2002 Aug; 90(4):353-7. PubMed ID: 12161221
[TBL] [Abstract][Full Text] [Related]
5. Synergy between intracoronary stenting and abciximab in improving angiographic and clinical outcomes of primary angioplasty in acute myocardial infarction.
Giri S; Mitchel JF; Hirst JA; McKay RG; Azar RR; Mennett R; Waters DD; Kiernan FJ
Am J Cardiol; 2000 Aug; 86(3):269-74. PubMed ID: 10922431
[TBL] [Abstract][Full Text] [Related]
6. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction.
Stone GW; Grines CL; Cox DA; Garcia E; Tcheng JE; Griffin JJ; Guagliumi G; Stuckey T; Turco M; Carroll JD; Rutherford BD; Lansky AJ;
N Engl J Med; 2002 Mar; 346(13):957-66. PubMed ID: 11919304
[TBL] [Abstract][Full Text] [Related]
7. Prospective evaluation of early abciximab and primary percutaneous intervention for patients with ST elevation myocardial infarction complicated by cardiogenic shock: results of the REO-SHOCK trial.
Zeymer U; Tebbe U; Weber M; Vohringer HF; Jaksch R; Bischoff KO; Toepel W; Marsalek P; Horn S; Neuhaus KL;
J Invasive Cardiol; 2003 Jul; 15(7):385-9. PubMed ID: 12840235
[TBL] [Abstract][Full Text] [Related]
8. Systematic direct angioplasty and stent-supported direct angioplasty therapy for cardiogenic shock complicating acute myocardial infarction: in-hospital and long-term survival.
Antoniucci D; Valenti R; Santoro GM; Bolognese L; Trapani M; Moschi G; Fazzini PF
J Am Coll Cardiol; 1998 Feb; 31(2):294-300. PubMed ID: 9462570
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of optimal or "stent-like"balloon angioplasty in acutemyocardial infarction: the CADILLAC trial.
Cox DA; Stone GW; Grines CL; Stuckey T; Cohen DJ; Tcheng JE; Garcia E; Guagliumi G; Iwaoka RS; Fahy M; Turco M; Lansky AJ; Griffin JJ; Mehran R;
J Am Coll Cardiol; 2003 Sep; 42(6):971-7. PubMed ID: 13678914
[TBL] [Abstract][Full Text] [Related]
10. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators.
Lincoff AM; Califf RM; Moliterno DJ; Ellis SG; Ducas J; Kramer JH; Kleiman NS; Cohen EA; Booth JE; Sapp SK; Cabot CF; Topol EJ
N Engl J Med; 1999 Jul; 341(5):319-27. PubMed ID: 10423466
[TBL] [Abstract][Full Text] [Related]
11. Coronary artery stenting for suboptimal PTCA results in acute myocardial infarction in patients treated with Abciximab: early and six-month outcome.
Murdock DK; Logemann T; Hoffmann MT; Olson KJ; Engelmeier RS
Cathet Cardiovasc Diagn; 1997 Oct; 42(2):173-9. PubMed ID: 9328702
[TBL] [Abstract][Full Text] [Related]
12. Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial.
Valgimigli M; Percoco G; Malagutti P; Campo G; Ferrari F; Barbieri D; Cicchitelli G; McFadden EP; Merlini F; Ansani L; Guardigli G; Bettini A; Parrinello G; Boersma E; Ferrari R;
JAMA; 2005 May; 293(17):2109-17. PubMed ID: 15870414
[TBL] [Abstract][Full Text] [Related]
13. Persistent coronary no flow after wire insertion is an early and readily available mortality risk factor despite successful mechanical intervention in acute myocardial infarction: a pooled analysis from the STRATEGY (Single High-Dose Bolus Tirofiban and Sirolimus-Eluting Stent Versus Abciximab and Bare-Metal Stent in Acute Myocardial Infarction) and MULTISTRATEGY (Multicenter Evaluation of Single High-Dose Bolus Tirofiban Versus Abciximab With Sirolimus-Eluting Stent or Bare-Metal Stent in Acute Myocardial Infarction Study) trials.
Valgimigli M; Campo G; Malagutti P; Anselmi M; Bolognese L; Ribichini F; Boccuzzi G; de Cesare N; Rodriguez AE; Russo F; Moreno R; Biondi-Zoccai G; Penzo C; Díaz Fernández JF; Parrinello G; Ferrari R
JACC Cardiovasc Interv; 2011 Jan; 4(1):51-62. PubMed ID: 21251629
[TBL] [Abstract][Full Text] [Related]
14. Outcome in elderly patients undergoing primary coronary intervention for acute myocardial infarction: results from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.
Guagliumi G; Stone GW; Cox DA; Stuckey T; Tcheng JE; Turco M; Musumeci G; Griffin JJ; Lansky AJ; Mehran R; Grines CL; Garcia E
Circulation; 2004 Sep; 110(12):1598-604. PubMed ID: 15353506
[TBL] [Abstract][Full Text] [Related]
15. Abciximab improves 6-month clinical outcome after rescue coronary angioplasty.
Petronio AS; Musumeci G; Limbruno U; De Carlo M; Baglini R; Paterni G; Grazia Delle Donne M; Caravelli P; Nardi C; Mariani M
Am Heart J; 2002 Feb; 143(2):334-41. PubMed ID: 11835040
[TBL] [Abstract][Full Text] [Related]
16. Effect of Abciximab Therapy in Patients Undergoing Coronary Angioplasty for Acute ST-Elevation Myocardial Infarction Complicated by Cardiogenic Shock.
De Felice F; Tomassini F; Fiorilli R; Gagnor A; Parma A; Cerrato E; Musto C; Nazzaro MS; Varbella F; Violini R
Circ J; 2015; 79(7):1568-74. PubMed ID: 25912694
[TBL] [Abstract][Full Text] [Related]
17. Optimizing the use of abciximab and intracoronary stents in patients with acute ST elevation myocardial infarction.
Velianou JL; Al-Suwaidi J; Mathew V
Am J Cardiovasc Drugs; 2002; 2(5):315-22. PubMed ID: 14727961
[TBL] [Abstract][Full Text] [Related]
18. Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction. EPIC investigators.
Lefkovits J; Ivanhoe RJ; Califf RM; Bergelson BA; Anderson KM; Stoner GL; Weisman HF; Topol EJ
Am J Cardiol; 1996 May; 77(12):1045-51. PubMed ID: 8644655
[TBL] [Abstract][Full Text] [Related]
19. Prediction of 1-year clinical outcomes using the SYNTAX score in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a substudy of the STRATEGY (Single High-Dose Bolus Tirofiban and Sirolimus-Eluting Stent Versus Abciximab and Bare-Metal Stent in Acute Myocardial Infarction) and MULTISTRATEGY (Multicenter Evaluation of Single High-Dose Bolus Tirofiban Versus Abciximab With Sirolimus-Eluting Stent or Bare-Metal Stent in Acute Myocardial Infarction Study) trials.
Garg S; Sarno G; Serruys PW; Rodriguez AE; Bolognese L; Anselmi M; De Cesare N; Colangelo S; Moreno R; Gambetti S; Monti M; Bristot L; Bressers M; Garcia-Garcia HM; Parrinello G; Campo G; Valgimigli M;
JACC Cardiovasc Interv; 2011 Jan; 4(1):66-75. PubMed ID: 21251631
[TBL] [Abstract][Full Text] [Related]
20. Abciximab therapy improves 1-month survival rate in unselected patients with acute myocardial infarction undergoing routine infarct artery stent implantation.
Antoniucci D; Valenti R; Migliorini A; Moschi G; Trapani M; Buonamici P; Cerisano G; Bolognese L; Santoro GM
Am Heart J; 2002 Aug; 144(2):315-22. PubMed ID: 12177651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
